Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar

VANCOUVER, BCJan. 16, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, is pleased to announce that its shares are now successfully listed on the Frankfurt Stock Exchange (FSE) under the trading symbol “9L2”. Their listing marks a significant milestone for the Company as it expands its global presence, now cross-listed on both the TSX Venture Exchange and the FSE, providing increased visibility and access to a broader pool of international investors.

Are you an angel?

Public Announcements

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…

Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…

Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th

VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…